HLA-E and cancer: Results: Our findings revealed that CD56+CD16+ and CD56−CD16− NK cells exhibited reduced cytotoxicity, mainly through HLA-E-expressing senescent cancer cells interacting with NK cells inhibitory receptor, leading to NK cell dysfunction and reduced XCL2 expression, which might impair cDC1 recruitment.